Connect with us

Hi, what are you looking for?

Jewish Business News


Brainsway Receives CE Approval for Its System to Treat Neuropathic Chronic Pain


/ By Ilan Shavit /

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.
Brainsway Ltd. (TASE:BRIN) announced today that it has received CE Mark enabling commercialization of its Deep TMS system to treat neuropathic chronic pain (“neuropathic pain”) in the European Union and the countries in Asia and Latin America that recognize the CE Mark.

“Neuropathic pain is the sixth indication for which Deep TMS has achieved CE Mark approval, ” commented Uzi Sofer, Brainsway’s CEO. “Previous CE Marks were for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson’s diseases and post-traumatic stress disorder. As our therapeutic pipeline continues to expand, it is very exciting to continue to bring proven new Deep TMS treatments to market.”

About Brainsway Ltd.

Brainsway is the developer Deep TMS (Transcranial Magnetic Stimluation) systems – novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson’s disease, Alzheimer’s disease, autism and post-traumatic stress disorder. The company initial focus is the treatment of major depression. Brainsway technology  is based on patents filed by the U.S. National Institute of Health (NIH) and by the company.

Brainsway has an exclusive license from the NIH for the patent and technology.   Headquartered in Jerusalem, Israel, the company’s ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol ‘BRIN’.




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.